"While this only affects 7%-8% of the overall population, we believe it has significant implications for GILD as it sets precedent for other payers and raises uncertainties on the overall size of the HCV market."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.